NCT07183423Recruiting
Novel Skin Barrier Product Versus Petrolatum for Skin Barrier Dysfunction
A Pilot Double-Blind Randomized Controlled Trial on the Efficacy and Safety of a Novel Skin Barrier Product Versus Petrolatum in Individuals With Skin Barrier Dysfunction
Source: ClinicalTrials.gov · Last updated 19 Sept 2025 · Not updated for over 12 months - ask the site whether it is still open
Brief summary (registry, in English)
The goal of this clinical trial is to learn if a novel barrier topical product works to treat barrier dysfunction in adults. It will also learn about the safety of the novel barrier topical product. The main questions it aims to answer are: Does the novel barrier topical product improve skin hydration, skin sebum, redness, and pigmentation? Does it improve subjective dryness and itch? Researchers will compare the novel barrier topical product to petrolatum (a gold standard occlusive barrier repair agent) to see how they are comparable in treating skin barrier dysfunction. Participants will: Apply the novel barrier topical product or petrolatum twice a day for 28 days Visit the clinic once a week for checkups and tests Keep a diary of their application of the assigned product
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 26 (estimated)
- First submitted
- 14 Sept 2025
- Start date
- 31 Aug 2025
- Primary completion date
- Sept 2025
- Lead sponsor
- Makati Medical Center
- Diseases
- Atopic dermatitis (eczema), Psoriasis
- NCT number
- NCT07183423
What you commit to
- Study type: Interventional
- Planned participants: 26
- From 31 Aug 2025 to the primary completion date, Sept 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of corticosteroids, calcineurin inhibitors, biologics, or phototherapy within 2 weeks
Other illness
- Failure to meet any of the above inclusion criteria
- Open wounds or evidence of secondary infection at test sites
- Known or suspected hypersensitivity to the interventional product (or its ingredients) or petrolatum
- Refusal or failure to comply with the schedule of visits at the test site.
Other
- Severe atopic dermatitis or psoriasis requiring systemic or high-potency topical treatment
- Pregnant or breastfeeding women
- Multiple nevi, tattoos, dense body hair in the test areas
- Debilitated or immunocompromised subjects
Who the study is looking for
- Clinical diagnosis of mild skin barrier dysfunction, including:
- Mild to moderate atopic dermatitis, defined as SCORAD ≤ 50, and/or not currently requiring topical corticosteroids or immunomodulators.
- Mild to moderate chronic plaque psoriasis, defined as total body surface area (BSA) involved: ≤3% to 10%.
- Contact dermatitis
- Seasonal xerosis or clinically evident skin dryness
- Symmetrical or bilateral test areas available (volar forearm)
- Willing and able to provide informed consent and adhere to study procedures
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| VMV Skin Research Center & Clinics Coordinator of this site? Confirm its status | Makati City | Philippines | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.